. 2018 Jul 26;8:241. doi: 10.3389/fonc.2018.00241

Table 1.

Study characteristics of the included RCTs evaluating PCI.

Study	Year of publication	Local treatment	Stage	Brain imaging	PCI dose	Primary endpoint	N^a	Systematic Follow-up for BM
VALG	1981	RT alone	All^b	Radionuclide scan	10 Gy × 2 Gy	BM rate	281	No

MDACC	1984	Chemo-RT	I–III	Radionuclide scan/CT scan	10 Gy × 3 Gy	CNS metastases rate	97	No
MDACC	1984	RT alone	I–III	Radionuclide scan/CT scan	10 Gy × 3 Gy	CNS metastases rate	97	No

RTOG 8403	1991	RT alone	I–III	CT scan	10 Gy × 3 Gy	Time to BM	187	No
RTOG 8403	1991	Surgery and RT	I–III	CT scan	10 Gy × 3 Gy	Time to BM	187	No

SWOG	1998	Chemo-RT	III	Unclear	15 Gy × 2–2.5 Gy	OS rate	226	Not reported
SWOG	1998	RT alone	III	Unclear	15 Gy × 2–2.5 Gy	OS rate	226	Not reported

RTOG 0214	2012	Chemo-RT	III	MRI scan	15 Gy × 2 Gy	OS rate	340	Yes

Li	2015	Surgery-chemo	IIIA	MRI scan	10 Gy × 3 Gy	DFS	156	Yes

NVALT-11	2018	RT alone	III	CT scan/MRI scan	18 Gy × 2 Gy/12 Gy × 2.5 Gy/10 Gy × 3 Gy	Symptomatic BM rate	175	Yes

^aNumber of eligible patients.

^bAll inoperable patients; stage not clear.

PCI, prophylactic cranial irradiation; RT, radiotherapy; Chemo; chemotherapy; BM, brain metastases; CNS, central nervous system; OS, overall survival; DFS, disease-free survival; RCTs, randomized controlled trials.